WASHINGTON, Nov. 9, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the following upcoming investor conferences in November 2023:
The Stifel 2023 Healthcare Conference on Tuesday, November 14, 2023. A corporate presentation is scheduled for 4:10 p.m. Eastern Time.
The Jefferies 2023 London Healthcare Conference on Thursday, November 16, 2023. A corporate presentation is scheduled for 2:00 p.m. Greenwich Mean Time (9:00 a.m. Eastern Time).
The corporate presentations given at the Stifel and Jefferies conferences may be accessed live on Vanda's corporate website, www.vandapharma.com. Investors should click on the Investors tab and follow the links under Recent Events. Investors are advised to go to the conference websites at least 15 minutes early to register, download, and install any necessary software or presentations. Links to the archived conferences will be available on Vanda's website for a period of approximately 30 days.
About Vanda Pharmaceuticals Inc.
Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on X @vandapharma.
Corporate Contact:
Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer
Vanda Pharmaceuticals Inc.
202-734-3400
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$4.90 |
Daily Change: | -0.02 -0.41 |
Daily Volume: | 388,822 |
Market Cap: | US$285.620M |
November 06, 2024 October 14, 2024 September 19, 2024 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB